Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 20/20 | 0.83 |
| ▸ | TDO2 | P48775 | 19/20 | 0.83 |
| ▸ | IDO2 | Q6ZQW0 | 11/20 | 0.83 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | APAF1 | O14727 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | MITF | O75030 | 1/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18133826 | 0.91 | IDO1 (1.00) | IDO1TDO2IDO2MEN1APAF1 | |
| SCHEMBL18059859 | 0.90 | IDO1 (1.00) | IDO1TDO2IDO2MEN1APAF1 | |
| SCHEMBL18059864 | 0.90 | IDO1 (1.00) | IDO1TDO2IDO2MEN1APAF1 | |
| SCHEMBL18133821 | 0.89 | IDO1 (0.68) | IDO1TDO2IDO2 | |
| SCHEMBL30639081 | 0.83 | IDO1 (0.78) | IDO1TDO2IDO2MEN1APAF1 | |
| SCHEMBL26614148 | 0.83 | IDO1 (0.77) | IDO1TDO2IDO2MEN1APAF1 | |
| SCHEMBL31382861 | 0.83 | IDO1 (0.77) | IDO1TDO2IDO2MEN1APAF1 | |
| SCHEMBL18133818 | 0.83 | IDO1 (0.78) | IDO1TDO2IDO2MEN1APAF1 | |
| SCHEMBL18136220 | 0.82 | IDO1 (1.00) | IDO1TDO2IDO2 | |
| SCHEMBL17830811 | 0.82 | TDO2 (1.00) | IDO1TDO2IDO2MEN1APAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160297822-A1 | N-benzyl tryptanthrin derivative, and preparation method and application thereof | FUDAN UNIVERSITY (CN) | 2016-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297822-A1 | N-benzyl tryptanthrin derivative, and preparation method and application thereof | IDO1, IDO2, TPH1 | IDO1 1/4885TDO2 5/4885IDO2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.